Compare CAR & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAR | KNSA |
|---|---|---|
| Founded | 1946 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Rental/Leasing Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.2B | 3.5B |
| IPO Year | 1998 | 2018 |
| Metric | CAR | KNSA |
|---|---|---|
| Price | $181.68 | $53.64 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $136.57 | $60.86 |
| AVG Volume (30 Days) | ★ 5.8M | 795.8K |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 50.71 | ★ 225.00 |
| EPS | N/A | ★ 0.27 |
| Revenue | ★ $11,652,000,000.00 | $677,564,000.00 |
| Revenue This Year | $2.10 | $37.48 |
| Revenue Next Year | $1.81 | $17.87 |
| P/E Ratio | ★ N/A | $198.13 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $85.96 | $25.71 |
| 52 Week High | $847.70 | $54.31 |
| Indicator | CAR | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 42.16 | 68.82 |
| Support Level | $126.54 | $40.67 |
| Resistance Level | $847.70 | N/A |
| Average True Range (ATR) | 101.76 | 2.21 |
| MACD | -37.84 | 1.08 |
| Stochastic Oscillator | 3.77 | 93.68 |
Avis Budget Group Inc is a provider of mobility solutions through its three brands Avis, Budget and Zipcar, as well as several other brands, well recognized in their respective markets. Its brands offer a range of options, from car and truck rental to car sharing. The company operates in two reportable business segments: Americas - (i) vehicle rental operations in North America, South America, Central America and the Caribbean, (ii) car sharing operations in certain of these markets, and (iii) licensees in the areas in which do not operate directly. International - consisting of (i) vehicle rental operations in Europe, the Middle East, Africa, Asia and Australasia, (ii) car sharing operations in certain of these markets, and (iii) licensees in the areas in which do not operate directly.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.